Recent Press Releases

First half year 2014: Boehringer Ingelheim meets challenges

Net sales of around €6.5 billion achieved in the first half year Preparations for additional product launches in full swing Initiative to improve cost structure launched Ingelheim,...

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME) TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN...

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014

Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 7% sales growth in local currencies driven by Levemir® and Victoza® Sales increased by 7% in...

Regeneron Reports Second Quarter 2014 Financial and Operating Results

- Second quarter 2014 EYLEA® (aflibercept) Injection global net sales increased 53% to $662 million (consisting of $415 million in the U.S. and $247 million in rest of world(1)) versus second...

GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD

New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD

RESEARCH TRI

Screening and Drug Therapy Predicted to Make Hepatitis C a Rare Disease

Screening and Drug Therapy Predicted to Make Hepatitis C a Rare Disease Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in...

Merck Completes Tender Offer to Acquire Idenix

Merck Completes Tender Offer to Acquire Idenix WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced the successful completion of...

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 - Second Quarter 2014 GAAP Earnings Per Diluted Share of $0.28 - - 82% Increase in...

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone

RIDGEFIELD, Conn.

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening

THOUSAND OAKS, Calif. and

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK, Aug. 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing...

Allergan Files Lawsuit in Federal Court against Valeant and Pershing Square for Violations of Federal Securities Laws

Complaint Alleges Pershing Square and Valeant Circumvented Insider Trading Laws and Violated SEC Rule 14e-3 Allergan Believes Pershing Square and Valeant Have Failed to Disclose Material...

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif.,...

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Third product from the BI-Lilly Diabetes alliance to be approved by FDA

RIDGEFIELD, Conn., and INDIANAPO

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) CHESHIRE, Conn., Aug 01, 2014 (BUSINESS WIRE) -- Alexion...

GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL

GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL Issued: 31 July 2014, London UK GlaxoSmithKline plc (LSE/NYSE: GSK) and...

FDA approves Jardiance to treat type 2 diabetes

The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2...

Teva Reports Second Quarter 2014 Results

Teva Reports Second Quarter 2014 Results Revenues of $5.0 billion, up 2% compared to the second quarter of 2013. Non GAAP operating income of $1.4 billion, an increase of 8%. GAAP operating...